Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.

Related Articles Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Jun 07;: Authors: Park KT, Sceats L, Dehghan M, Trickey AW, Wren A, Wong JJ, Bensen R, Limketkai BN, Keyashian K, Kin C Abstract BACKGROUND: Perioperative vedolizumab (VDZ) and anti-tumour necrosis factor (TNFi) therapies are implicated in causing post-operative complications in inflammatory bowel disease (IBD). AIM: To compare the risk of surgical site infections (SSIs) between VDZ- and TNFi-treated IBD patients in…

Read More

Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.

Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development. Gastroenterology. 2018 May 29;: Authors: Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U Abstract BACKGROUND & AIMS: Exposure to biologic and immunosuppressant agents during breastfeeding is controversial and there are limited data on safety. We investigated whether biologics are detectable in breast milk from women receiving treatment for inflammatory bowel diseases (IBD) and whether breastfeeding while on treatment is associated with infections or developmental delays. METHODS:…

Read More

Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials.

Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials. J Crohns Colitis. 2018 May 17;: Authors: Feagan BG, Bhayat F, Khalid M, Blake A, Travis SPL Abstract Background and Aims: Vedolizumab, a humanised monoclonal antibody for the treatment of inflammatory bowel disease, selectively blocks gut lymphocyte trafficking. This may reduce the risk of respiratory tract infections [RTIs] compared with systemic immunosuppressive therapies. To assess this possibility, we evaluated the rates of RTIs in clinical trials of vedolizumab. Methods: Patient-level data from Phase 3 randomised…

Read More

Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis?

Related Articles Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis? Dig Dis Sci. 2018 May 19;: Authors: Chandradas S, Khalili H, Ananthakrishnan A, Wayman C, Reidel W, Waalen J, Konijeti GG Abstract BACKGROUND: Patients with ulcerative colitis (UC) are at an increased risk of Clostridium difficile infection (CDI) compared with the general population. Recent data suggest that obesity also increases the risk of CDI. AIMS: To examine whether obesity influences the risk of CDI among patients with UC. STUDY: We conducted a retrospective cross-sectional…

Read More

Rising Incidence of Intestinal Infections in Inflammatory Bowel Disease: A Nationwide Analysis.

Rising Incidence of Intestinal Infections in Inflammatory Bowel Disease: A Nationwide Analysis. Inflamm Bowel Dis. 2018 May 02;: Authors: Barber GE, Hendler S, Okafor P, Limsui D, Limketkai BN Abstract Background: Intestinal infections are common in patients with inflammatory bowel disease (IBD) and may mimic IBD flares. In this study, we estimate the changing incidence of intestinal infections among IBD hospitalizations and assess the impact of intestinal infections on key hospitalization metrics. Methods: The National Inpatient Sample (NIS) was analyzed for hospitalizations from IBD between 1998 and 2014. Intestinal infections…

Read More

CMV Disease in IBD: Comparison of Diagnostic Tests and Correlation with Disease Outcome.

Related Articles CMV Disease in IBD: Comparison of Diagnostic Tests and Correlation with Disease Outcome. Inflamm Bowel Dis. 2018 Apr 30;: Authors: Johnson J, Affolter K, Boynton K, Chen X, Valentine J, Peterson K Abstract Background: Significance of cytomegalovirus (CMV) in inflammatory bowel disease (IBD) is unclear due to pathobiology, numerous CMV tests, and disparate treatment outcomes. Methods: Retrospective chart review was done on patients with positive qualitative CMV tissue polymerase chain reaction (PCR) from 2005-2013 at a tertiary referral hospital. Frequency of PCR+, hematoxylin and eosin staining(HE)+, histopathology and…

Read More

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2018 Apr 12;: Authors: Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel MF, Dray-Spira R Abstract BACKGROUND & AIMS: The risk of infection associated with tumor necrosis factor antagonists (anti-TNF) and thiopurines (combination therapy) is uncertain. We assessed the risk of serious and opportunistic infections in patients with IBD treated with thiopurine monotherapy, anti-TNF monotherapy, or combination therapy in a large cohort of patients in France. METHODS: We performed a nationwide population-based study of patients…

Read More

Systemic Inflammatory Responses in Ulcerative Colitis Patients and Clostridium difficile Infection.

Systemic Inflammatory Responses in Ulcerative Colitis Patients and Clostridium difficile Infection. Dig Dis Sci. 2018 Apr 12;: Authors: Limsrivilai J, Rao K, Stidham RW, Govani SM, Waljee AK, Reinink A, Johnson L, Briggs E, Higgins PDR Abstract BACKGROUND/AIMS: Finding differences in systemic inflammatory response in ulcerative colitis (UC), UC with Clostridium difficile infection (CDI), and CDI could lead to a better ability to differentiate between UC with symptomatic CDI and UC with C. difficile colonization, and could identify specific inflammatory pathways for UC or CDI, which could be therapeutic targets.…

Read More

Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy.

Immunogenicity of Quadrivalent Influenza Vaccine for Patients with Inflammatory Bowel Disease Undergoing Immunosuppressive Therapy. Inflamm Bowel Dis. 2018 Mar 09;: Authors: Shirai S, Hara M, Sakata Y, Tsuruoka N, Yamamoto K, Shimoda R, Gomi Y, Yoshii H, Fujimoto K, Iwakiri R Abstract Background and Aims: No reports have described the immunogenicity and boosting effect of the quadrivalent inactivated influenza vaccine (QIV) in adults with inflammatory bowel disease. Methods: Adults with Crohn’s disease or ulcerative colitis were randomly assigned to a single vaccination group or booster group, and a QIV was…

Read More
<< Go Back